Rectal Cancer
Conditions
Keywords
laparoscopic surgery, rectal carcinoma, phase II trial
Brief summary
The purpose of this study is to examine the technical and oncological feasibility of laparoscopic surgery for rectal carcinoma
Detailed description
Recently reported randomized controlled trials demonstrated that laparoscopic surgery was comparable or superior to open surgery regarding the long-term outcome for colon and rectosigmoidal carcinoma; however, controversy persists regarding the appropriateness of laparoscopic surgery for patients with rectal carcinoma because of the uncertainty of the long-term outcome, and of concerns over the safety of the procedure. In Japan, lateral lymph node dissection combined with total mesorectal excision remains the standard surgical procedure for patients with advanced lower rectal carcinoma, and lateral lymph node dissection by laparoscopy is still an unexplored frontier. To examine the technical and oncological feasibility of laparoscopic surgery for rectal carcinoma, a phase II trial will be conducted in patients with a preoperative diagnosis of stage 0/I rectal carcinoma, under the direction of the Japan Society of Laparoscopic Colorectal Surgery, to which leading hospitals in laparoscopic surgery for colorectal carcinoma in Japan are members.
Interventions
Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
Sponsors
Study design
Eligibility
Inclusion criteria
1. Histologically proven rectal carcinoma. 2. Tumor located in the rectum. 3. Clinical Tis, T1, T2 N0 M0 4. Without multiple lesions other than carcinoma in situ 5. Tumor size \<8 cm. 6. Sufficient organ function. 7. No bowel obstruction. 8. No history of major colorectal surgery. 9. No history of chemotherapy or radiotherapy. 10. Provide written informed consent.
Exclusion criteria
1. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ. 2. Pregnant or lactating women. 3. Severe mental disease. 4. Severe pulmonary emphysema, interstitial pneumonitis or ischemic heart disease. 5. Continuous systemic steroid therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | 5 year |
Secondary
| Measure | Time frame |
|---|---|
| anastomotic leakage rate | 1 month |
Countries
Japan